Furthermore, a preclinical study has confirmed that mice inoculated with metastatic breast cancer cells and treated with neoadjuvant anti-PD-1 have increased numbers of tumor-specific CD8+ T cells in the peripheral blood and organs, and they experience a longer survival period than their counterparts treated with adjuvant anti–PD-1 (23). The gene discussed is CD8A; the disease is neoplasm.